Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-03-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, led by CASGEVY and a broader pipeline in cardiovascular disease, autoimmune disease, oncology, and regenerative medicine.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First Approval, Still a Proof-of-Platform Story
A real commercial foothold and a strong cash balance create credible upside, but most 2031 value still depends on new human proof beyond CASGEVY. The setup is attractive if one more franchise works, yet partner control and regulatory friction keep the story from being simple.

Analysis

Thesis
CRISPR Therapeutics has enough cash, one real commercial beachhead, and enough 2026-2027 shots on goal to plausibly graduate from a single-asset gene-editing story into a multi-franchise platform by 2031, but the rerating depends on follow-on human proof and better control of commercialization surfaces than it has today.
Last Economy Alignment
AI should make biological design, target selection, and platform iteration cheaper and faster, which helps CRISPR expand its shot count. But value still gets bottlenecked by human clinical proof, regulation, manufacturing, and Vertex-controlled commercialization, so the benefit is real but not infrastructure-like.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.3x (from 5 most recent analyses)
Reasoning
Today’s valuation still reflects cash, one approved franchise, and a wide but unproven option set. If CASGEVY becomes a durable cash engine and one or two additional programs show convincing human proof, investors can re-rate the business from single-asset skepticism to a diversified gene-editing platform. That supports meaningful upside, but partner control and regulatory gates argue against assuming a euphoric outcome.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risks are proof and control, not solvency. CRISPR still needs 2026-2027 data to show its platform works beyond CASGEVY, and its one approved asset monetizes through Vertex’s launch and access stack. If follow-on programs disappoint or commercialization stays slow, the stock can remain trapped as cash plus optionality despite real scientific progress.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They own gene-editing know-how, manufacturing capability, and one approved therapy, so cheaper AI-driven biology should help them design and advance more programs. But regulators, complex treatment logistics, and Vertex controlling much of the first commercial surface mean they capture AI-era upside only if fresh clinical proof keeps arriving.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$70.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case